Inspire Medical Faces Securities Class Action Over Inspire V Rollout as Lead‑Plaintiff Deadline Nears

Overview

• The suit claims Inspire misled investors about market demand for the Inspire V sleep‑apnea device and its commercial readiness.
• Plaintiffs cite rollout failures, including incomplete training and onboarding, gaps in IT and customer approvals, insurer claims software not updated, and Medicare billing not in place at launch.
• The alleged class period runs from Aug. 6, 2024 through Aug. 4, 2025, with the case pending in the U.S. District Court for the District of Minnesota.
• Notices from Rosen, Schall, DJS, The Gross Law Firm, Glancy Prongay & Murray, and Hagens Berman invite shareholders to contact them, and no class has been certified.
• One investor notice attributes a $42.04, 32.4% stock drop and a more‑than‑80% 2025 EPS guidance cut to the Aug. 4, 2025 disclosure about the Inspire V rollout and an inventory glut of the prior device.